Last reviewed · How we verify
NCT05106725
Wearable Devices and Biomarkers Project (Healthiomics)
trial in Brain Cancer in 3,500 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | CureScience |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 3,500 |
| Start date | 11 October 2021 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across United States |
Conditions studied
- Brain Cancer — all drugs for Brain Cancer →
- Neurological Disorder — all drugs for Neurological Disorder →
- Neurological Cancer — all drugs for Neurological Cancer →
Sponsor
CureScience
Who can join
18 and older, any sex, with Brain Cancer or Neurological Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to collect clinical data, biological specimens (e.g., blood, tumor, cerebrospinal fluid, urine sample, etc.), and digital health data from patients with tumors, cancer and/or neurological disorders in order to perform research studies that could advance patient care. By collecting these specimens, the investigators plan to create and maintain a biorepository to make data and specimens available to collaborating investigators performing research to discover predictive biomarkers, patterns of care, and personalized treatments that could directly improve the care of our patients through focused proof-of-concept clinical trials.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficient use of binned data for imputing univariate time series data.
Darji J, Biswas N, Padul V, Gill J, et al · · 2024 · PMID 39234189 · DOI 10.3389/fdata.2024.1422650
Verify or expand the search:
- PubMed search for NCT05106725
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Brain Cancer
Currently open trials in the same condition.
- NCT07374692 — Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors · NA · recruiting
- NCT06640582 — TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas · Phase 1, PHASE2 · recruiting
- NCT06058988 — Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer · Phase 2 · recruiting
- NCT05954858 — Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma · NA · recruiting
- NCT05943262 — Record Voxel Rate Nonlinear Optical Microscope to Unravel Brain Connectome and Signaling · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05106725 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CureScience
- Last refreshed: 21 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05106725.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing